Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population

BACKGROUND: Dalbavancin is a lipoglycopeptide with activity against Gram-positive pathogens responsible for ABSSSI, including methicillin-resistant Staphylococcus aureus (MRSA), and is FDA-approved as a single- or two-dose regimen. The objective of this study was to assess efficacy and safety of dal...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgiades, Benjamin, Rappo, Urania, Gonzalez, Pedro L, McGregor, Jennifer S, Chen, Jie, McCarthy, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631734/
http://dx.doi.org/10.1093/ofid/ofx163.114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631734/
http://dx.doi.org/10.1093/ofid/ofx163.114

Ejemplares similares